AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01067183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: portable biofeedback tool and relaxation breathing technique
Description: The intervention group were trained in relaxation breathing technique and the use of a portable biofeedback tool that informs them of the success of the technique...thus behavioral therapy using a biofeedback device
Study NCT02152683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renova
Description: Low- Intensity Shockwave
Study NCT03708991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IVF combined with PGT-A
Description: trophectoderm biopsy to test the ploidy state of the IVF embryos
Study NCT03708991 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ICSI combined with PGT-A
Description: trophectoderm biopsy to test the ploidy state of the ICSI embryos
Study NCT03584919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: patients received oral doxycycline 100 milgrams bid for 15 days
Study NCT03584919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime Axetil 500Mg Tab
Description: patients received cefuroxime axetil 500 milgrams bid for 15 days
Study NCT03584919 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control subjects
Description: no intervention
Study NCT02237378 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG PET scan
Description: Following an overnight fast, subjects will be positioned in the Discovery 660 PET/VCT scanner. Following a scout scan to confirm patient positioning, low dose xray CT scan is performed for photon attenuation. A 20 minute dynamic PET scan is started simultaneously with 3 MBq/kg of N-13 ammonia to measure myocardial perfusion. Following N-13 decay,a 60 minute dynamic PET scan with 3 MBq/kg F-18- FDG to measure myocardial glucose uptake. Blood sampling for glucose and insulin will occur at pre specified time points throughout the scan.
Study NCT01746615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Vessel Analyzer
Description: retinal vessel diameter \& oxygen saturation
Study NCT01746615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bidirectional Fourier-Domain Optical Coherence Tomography (FDOCT)
Description: retinal blood velocity
Study NCT03235128 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ‗Urine analysis ‗Urine protein quantification ‗Serum albumin ‗Lipid profile.Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood.
Description: Specific tests Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood
Study NCT00471120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P2x7 assay
Description: compare P2X7 assay to biopsy
Study NCT01332162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Description: All patients will be pacing during two years
Study NCT01332162 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Pacing
Description: No Pacing during the first year. In the second year all patients will be pacing
Study NCT02252120 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supreme
Study NCT02518269 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Arthroplasty
Description: Hip Arthroplasty comparing 3 different bearings.
Study NCT01431742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEMA Buprenorphine
Description: buccal soluble film; applied to the buccal mucosa twice daily
Study NCT01294540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: E2609
Description: E2609 orally at varying ascending doses
Study NCT01294540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT02842099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA or TAC
Description: Taxol, Epirubincin, with or without Cyclophosphamide
Study NCT02842099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA or TAC
Description: Taxol, Epirubincin, with or without Cyclophosphamide
Study NCT02252120 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Tube
Study NCT04480762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1703
Description: SHR-1703
Study NCT04480762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo of the SHR-1703
Study NCT00058955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium oxybate, triazolam and pentobarbital
Description: sodium oxybate, triazolam and pentobarbital
Study NCT02842099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X
Description: Capecitabine
Study NCT00058955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium oxybate, triazolam and pentobarbital
Description: sodium oxybate, triazolam and pentobarbital
Study NCT00058955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium oxybate, triazolam and pentobarbital
Description: sodium oxybate, triazolam and pentobarbital
Study NCT03368287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit One, the activity tracker
Description: Activity tracker, Fitbit One, will be used for a week to evaluate the steps of daily life before the surgery and at the time of follow up.
Study NCT02631083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast, lunch, snack and dinner
Description: These meals (cereal, rice and bread meals) will be tested in subjects for their glycaemic response (CGMS) and substrate utilization (calorimeter)
Study NCT03660033 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG in delivery room
Description: See arm/group discussions
Study NCT03454217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Postoperative pain treatment with oxycodone
Study NCT03454217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Postoperative pain treatment with tramadol
Study NCT00875849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT00875849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00875849 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT04165161 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: search for a patent foramen ovale
Description: Injection of a contrast solution A - In the upper cellar territory with controlled ventilation without positive tele-expiratory pressure; B - In the upper cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O; C - In the lower cellar territory with controlled ventilation without positive tele-expiratory pressure; D - In the lower cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O;
Study NCT00569361 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Collection of nasal epithelial cells
Description: Collection of nasal epithelial cells by brushing
Study NCT01972828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLUID MANAGEMENT GUIDED WITH PRELOAD-DEPENDENCE PARAMETERS (VOLUVEN ®)
Description: in this arm, fluid loading is administered with an algorithm using preload dependence indexes. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
Study NCT01972828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STANDARD-GUIDED FLUID MANAGEMENT (VOLUVEN ®)
Description: in this arm, fluid loading is administered with an algorithm using central venous pressure. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
Study NCT02896023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human menopausal gonadotropin
Description: Induction of ovulation followed by ICSI
Study NCT01900314 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: 20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the sham arm.
Study NCT01900314 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: 20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the sham arm.
Study NCT03005756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Needle guiding robot
Description: This intervention is to evaluate the safety and efficacy of a needle guiding robot for assisting targeting in CT-guided radiofrequency ablation of hepatocelluar carcinomas.
Study NCT03537456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mRDX-02-17
Description: mRDX -02-17 is a dermal filler recommended for the correction and treatment of wrinkles and dermal depressions.~It is a sterile and viscous aqueous solution of hyaluronic acid in a concentration of 1.5% (p/v) with acetyl tetrapeptide-9 and palmitoyl tripeptide-5, as auxiliary ingredients which is administrated by intradermal injections.~This medical device encourages repair and restructuring of skin tissue and reduces the signs of aging.~mRDX -02-17 is indicated for patients with hypotrophic tissues, Crow's feet, Glogau III-IV, all skin photo types (Fitzpatrick I - VI) and a WSRS score (Wrinkle Severity Ranking Scale) from 2 to 5.
Study NCT03611062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Executive Functions Training
Description: The Windows 10-based VICT program invites children to rescue an animated character named Lubdub from a castle. The program consists of three challenging and child-friendly tasks that correspond to the three core EFs.
Study NCT03611062 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: VR Placebo Game
Description: In this game, children in the control group will use the VR hand controller to cast different types of spells (bees, bouncy balls, sparkler spells) to objects in the virtual world. Objects in the VR world will all react differently to a spell being cast so as to provide children a relaxing and EF-free gaming experience.
Study NCT01225744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be prepared under Good Manufacturing practice (GMP) and supplied by Merck KGaA (Darmstadt, Germany) as a solution for intravenous infusion. It will be made up into 250ml with N/Saline.~Dose administered is 400mg/m2 and will be given on day 1 and day 15 of a 28 day cycle.Cetuximab will always be administered first, i.e. the cetuximab infusion should be completed one hour before any chemotherapy begins. The cetuximab dose must always be based on the body surface area(BSA). There is no restriction for cetuximab in patients with a BSA > 2 m2 .
Study NCT01225744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Dose is 180mg/m2 made up into 250ml with 5% dextrose or 0.9% saline. It will be administered as a short infusion over 60-90 minutes after a 60 minute gap left after cetuximab administration. Irinotecan is administered on day 1 of the 28 day cycle.
Study NCT01225744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Dose is 100mg/m2 and will be made up into 250ml with 5% dextrose. It will be administered as a short infusion over 120 minutes after the 60 minute gap left after cetuximab administration. Oxaliplatin is administered on day 15 of the 28 day cycle.
Study NCT01225744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT
Description: UFT dose is 250mg/m2 and is given in three divided doses with calcium folate 30mg p.o. tds on days 1-21 of the 28 day cycle. The highest dose of UFT should be given in the morning if the dose cannot be divided equally.
Study NCT01684800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A. Desmopressin 10 microgram
Description: 1 orally disintegrating tablet every night during study period
Study NCT01684800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B: Desmopressin 25 microgram
Description: 1 orally disintegrating tablet every night during study period
Study NCT01684800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C: Placebo
Description: 1 orally disintegrating tablet every night during study period
Study NCT01815619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: on-site specimen evaluation
Description: The specimen will be evaluated on-site by a cytopathologist during the procedure to render a diagnosis
Study NCT01815619 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: off-site specimen evaluation
Description: The specimen will be evaluated off-site by a cytopathologist
Study NCT01286649 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Human autologous hair follicle cells
Description: Human autologous hair follicle cells suspended in cell medium
Study NCT01286649 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cell medium
Description: Cell medium
Study NCT03346317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: disposable balloon uterine stent
Description: The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.
Study NCT03346317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dried biological amnion graft
Description: Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane
Study NCT03346317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate tablets+dydrogesterone tablets
Description: oral estradiol valerate tablets+dydrogesterone tablets
Study NCT01748682 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A very low calorie diet of two different consistencies
Description: Liquid and normal consistency diet with a very low calorie diet will be given to patients pre-operatively in bariatric surgery
Study NCT01748682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A very low calorie diet of two different consistencies
Description: Liquid and normal consistency diet with a very low calorie diet will be given to patients pre-operatively in bariatric surgery
Study NCT02723422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prehabilitation visit/increased physical therapy post-TAVR
Description: Prior to TAVR, patients randomized to the intervention arm will meet with a licensed physical therapist for a 30-minute session in the ambulatory setting. Following TAVR, patients randomized to the intervention arm will receive 4 days per week of home-based physical therapy by a licensed physical therapist working for Revival Home Health Care
Study NCT02723422 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Arm
Description: Patients randomized to the usual care arm will receive home-based physical therapy for 2 days per week by Revival Home Health Care, which is the current standard of care.
Study NCT05967559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Flipped Learning Group
Description: The experimental group is the group that receives online flipped learning training.
Study NCT05967559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional learning Group
Description: The control group is the group that received traditional learning training.
Study NCT02298283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: is 1.8 mg/kg administrated by IV infusion
Study NCT02298283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1250 mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
Study NCT02298283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 35mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
Study NCT02298283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oncovin
Description: 1.4 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
Study NCT02298283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: 10 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
Study NCT02298283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 200 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D3 of 2 BEACOPP cycles, every 3 weeks
Study NCT02298283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine
Description: 100 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
Study NCT02298283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
Study NCT02298283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 µg/kg/j, SC, D9 until GB 1.0x109/L
Study NCT02298283 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 30 Grays
Description: 30 Gy radiation of sites initially diagnoses + 6Gy for residual sites, 3 to 4 weeks after D1 of BEACOPP cycle 2.
Study NCT04558242 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genix
Description: Low Level Light (LEDs)
Study NCT04558242 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Incandescent Bulbs Colored Red
Study NCT04063527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy
Description: combination of paclitaxel and carboplatin
Study NCT02261025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: 75-100mg,per day
Study NCT00688207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (Extended Release)
Description: open-label, single, oral, 4mg dose
Study NCT00870233 — intervention group
Intervention type: BEHAVIORAL
Intervention: online platform WEBCORE
Description: Enrollees will be sent weekly email reminders to login to WEBCORE from home. Participants will be expected to complete the questionnaire once pre-operatively and then weekly starting 7 days after surgery until the 6-week post-operative period has ended.
Study NCT01728233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
Study NCT01723696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C +prenatal vitamin
Description: Pregnant smoking women will be randomized to daily vitamin C (500 mg) versus daily placebo
Study NCT01723696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet+prenatal vitamin
Study NCT02778360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback NFT
Description: The ADHD@Home Device is composed of a software for NF Training deployed on a Windows tablet, and connected to an EEG headset and an amplifier.~The training is personalized according to patient's characteristics.
Study NCT02778360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate MPH
Description: Drug prescribed with a first titration period until an optimal dose.
Study NCT03095547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A
Description: Pharmacokinetic assessment Area Under the plasma concentration: time Curve (AUC) 0-t
Study NCT03095547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Pharmacokinetic assessment AUC 0-tau
Study NCT03095547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pharmacokinetic assessment AUC 0-tau
Study NCT03095547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: Pharmacokinetic assessment AUC 0-tau
Study NCT03095547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Pharmacokinetic assessment AUC 0-t
Study NCT03271294 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Exair Transvaginal Mesh
Description: Exair transvaginal mesh system for the treatment of pelvic organ prolapse
Study NCT01987947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two administrations by subcutaneous injection
Study NCT01987947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quilizumab
Description: Two administrations by subcutaneous injection
Study NCT00358072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postremission consolidation based on MRD status
Description: Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)